NO20092254L - Pulverformuleringer for valganciclovir - Google Patents

Pulverformuleringer for valganciclovir

Info

Publication number
NO20092254L
NO20092254L NO20092254A NO20092254A NO20092254L NO 20092254 L NO20092254 L NO 20092254L NO 20092254 A NO20092254 A NO 20092254A NO 20092254 A NO20092254 A NO 20092254A NO 20092254 L NO20092254 L NO 20092254L
Authority
NO
Norway
Prior art keywords
valganciclovir
powder formulations
dosage forms
pharmaceutical dosage
cytomegalovirus
Prior art date
Application number
NO20092254A
Other languages
English (en)
Other versions
NO339838B1 (no
Inventor
Martin Howard Infeld
Navnit Hargovindas Shah
Maria Oksana Bachynsky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39410167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092254(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20092254L publication Critical patent/NO20092254L/no
Publication of NO339838B1 publication Critical patent/NO339838B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer nye faste farmasøytiske doseformer av valganciclovir-hydroklorid for oral administrering, etter konstituering i vann. Disse nye farmasøytiske doseformer er anvendelige i behandling eller kontroll av virus så som herpes simplex virus og cytomegalovirus.
NO20092254A 2006-12-13 2009-06-11 Fast farmasøytisk doseform omfattende valganciclovir NO339838B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87463406P 2006-12-13 2006-12-13
PCT/EP2007/063151 WO2008071573A2 (en) 2006-12-13 2007-12-03 Powder formulation for valganciclovir

Publications (2)

Publication Number Publication Date
NO20092254L true NO20092254L (no) 2009-07-09
NO339838B1 NO339838B1 (no) 2017-02-06

Family

ID=39410167

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092254A NO339838B1 (no) 2006-12-13 2009-06-11 Fast farmasøytisk doseform omfattende valganciclovir

Country Status (31)

Country Link
US (6) US20080146591A1 (no)
EP (1) EP2101733B1 (no)
JP (1) JP5111517B2 (no)
KR (1) KR101116553B1 (no)
CN (1) CN101541310B (no)
AR (1) AR065541A1 (no)
AU (1) AU2007332640B2 (no)
BR (1) BRPI0720118B8 (no)
CA (1) CA2671470C (no)
CL (1) CL2007003564A1 (no)
CO (1) CO6220902A2 (no)
CR (1) CR10822A (no)
DK (1) DK2101733T3 (no)
ES (1) ES2391912T3 (no)
HR (1) HRP20121033T1 (no)
IL (1) IL198854A (no)
MA (1) MA31280B1 (no)
MX (1) MX2009005921A (no)
MY (1) MY152540A (no)
NO (1) NO339838B1 (no)
NZ (1) NZ577179A (no)
PE (1) PE20081578A1 (no)
PL (1) PL2101733T3 (no)
PT (1) PT2101733E (no)
RS (1) RS52457B (no)
RU (1) RU2440118C2 (no)
SI (1) SI2101733T1 (no)
TW (1) TWI341730B (no)
UA (1) UA93599C2 (no)
WO (1) WO2008071573A2 (no)
ZA (1) ZA200903840B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257294A2 (en) * 2008-03-07 2010-12-08 Ray W. Exley Treatment of herpes virus related diseases
CN102048677B (zh) * 2009-11-09 2014-03-05 杭州赛利药物研究所有限公司 一种盐酸缬更昔洛韦固体制剂及其制备方法
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
AU2013249708B2 (en) * 2012-04-20 2017-03-16 Annji Pharmaceutical Co., Ltd. Cyclopropanecarboxylate esters of purine analogues
RU2015132902A (ru) 2013-01-07 2017-02-09 Сам-А Фарм. Ко., Лтд. Новый быстрорастворимый состав гранул с улучшенной растворимостью
ES2629103T3 (es) * 2013-08-02 2017-08-07 Ali Raif Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulación en polvo de valganciclovir
CN104055746B (zh) * 2014-07-12 2017-06-30 河北仁合益康药业有限公司 一种盐酸缬更昔洛韦包衣片剂组合物
RU2720805C1 (ru) * 2019-05-22 2020-05-13 Общество с ограниченной ответственностью "Трейдсервис" Фармацевтическая композиция валганцикловира
EP3976198A4 (en) 2019-05-31 2023-07-19 Viracta Subsidiary, Inc. METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS
CN110613718A (zh) * 2019-09-19 2019-12-27 湖北科益药业股份有限公司 一种缬更昔洛韦组合物
CN110934823B (zh) * 2019-12-27 2022-03-01 湖北康源药业有限公司 一种盐酸缬更昔洛韦口服溶液及制备方法
WO2021161317A1 (en) * 2020-02-12 2021-08-19 Cts Chemical Industries Ltd. Stable pharmaceutical compositions comprising valgancyclovir and uses thereof
CN114028347B (zh) * 2021-11-30 2023-05-12 海南皇隆制药股份有限公司 注射用帕瑞昔布钠及其制备方法
CN115569113B (zh) * 2022-09-19 2023-11-10 江苏汉晨药业有限公司 一种盐酸缬更昔洛韦口服溶液

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880002139B1 (ko) 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5840890A (en) 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US6365196B1 (en) * 1997-10-03 2002-04-02 Smithkline Beecham Corporation Controlled release solid dosage forms of lithium carbonate
US6221917B1 (en) * 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition
EP1459739B1 (en) 2003-03-19 2008-01-02 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Non-hygroscopic pharmaceutical compositions containing non-hydrated quinoline carboxylic acids
CA2537132A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Amorphous valganciclovir hydrochloride
DE602005008721D1 (de) 2004-03-10 2008-09-18 Ranbaxy Lab Ltd Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid
BRPI0614870A2 (pt) 2005-08-22 2011-04-19 Novartis Ag composições farmacêuticas

Also Published As

Publication number Publication date
PE20081578A1 (es) 2008-11-12
ZA200903840B (en) 2010-03-31
NZ577179A (en) 2011-12-22
US11185588B2 (en) 2021-11-30
US20130150382A1 (en) 2013-06-13
PL2101733T3 (pl) 2013-02-28
EP2101733A2 (en) 2009-09-23
US20080146591A1 (en) 2008-06-19
RU2009126616A (ru) 2011-01-20
AR065541A1 (es) 2009-06-17
US20150057296A1 (en) 2015-02-26
UA93599C2 (en) 2011-02-25
AU2007332640B2 (en) 2011-04-07
WO2008071573A2 (en) 2008-06-19
JP2010513237A (ja) 2010-04-30
BRPI0720118B1 (pt) 2020-11-17
CR10822A (es) 2009-06-25
US20170266286A1 (en) 2017-09-21
ES2391912T3 (es) 2012-12-03
CA2671470A1 (en) 2008-06-19
KR20090086469A (ko) 2009-08-12
WO2008071573A3 (en) 2008-11-27
US20190117775A1 (en) 2019-04-25
US8889109B2 (en) 2014-11-18
SI2101733T1 (sl) 2012-12-31
KR101116553B1 (ko) 2012-03-13
RU2440118C2 (ru) 2012-01-20
MA31280B1 (fr) 2010-04-01
US9642911B2 (en) 2017-05-09
IL198854A (en) 2014-06-30
TWI341730B (en) 2011-05-11
BRPI0720118A2 (pt) 2014-01-14
TW200840585A (en) 2008-10-16
HRP20121033T1 (hr) 2013-01-31
CA2671470C (en) 2012-05-01
JP5111517B2 (ja) 2013-01-09
CO6220902A2 (es) 2010-11-19
MX2009005921A (es) 2009-06-17
US20180153998A1 (en) 2018-06-07
MY152540A (en) 2014-10-15
CN101541310B (zh) 2012-11-07
CL2007003564A1 (es) 2008-07-18
DK2101733T3 (da) 2013-02-04
CN101541310A (zh) 2009-09-23
PT2101733E (pt) 2012-10-30
EP2101733B1 (en) 2012-09-26
AU2007332640A1 (en) 2008-06-19
RS52457B (en) 2013-02-28
NO339838B1 (no) 2017-02-06
BRPI0720118B8 (pt) 2021-05-25
IL198854A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
NO20092254L (no) Pulverformuleringer for valganciclovir
NO20082376L (no) Farmasoytiske sammensetninger
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
NO20065190L (no) Farmasoytiske sammensetninger omfattende en amfifil stivelse
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20090628L (no) Pyridizinon derivativater
ECSP10010197A (es) Derivados de piridina y pirazina útiles en el tratamiento de trastornos de proliferación celular
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
MXPA05008866A (es) Pirimidinas sustituidas con indano inhibidoras de la replicacion del virus de inmunodeficiencia humana.
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
NO20052591L (no) Pyridopyrolizin og pyridoindolizinderivater
NO20064584L (no) Tetrahydropyridoindolderivater
UY30183A1 (es) Derivados de quinolina
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
NO20072055L (no) Fremgangsmater og sammensetninger for behandling av flaviviruser, pestiviruser og hepacivirus
UY32203A (es) Amino pirimidinas y su uso en terapia
CR8778A (es) Revestimientos de azucar y metodos para estos
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
MX2010004673A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos.
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
MX2010002733A (es) Terapia de intervalo para el tratamiento de tinnitus.
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees